Skip to content

Scilex Holding Company SCLX Derivative Liability, Noncurrent

Derivative Liability, Noncurrent at other companies

Ocular Therapeutix logo
Ocular TherapeutixOCUL

Other financials

Income statement

See full
Revenue$8.6M+72.1%
Gross profit$4.2M+15.1%
Operating income-$32.2M-15.3%
Net income-$45.7M-75.0%
EPS (diluted)-$6.28-178%

Balance sheet

See full
Cash & equivalents$3.4M-42.2%
Total debt$95.4M+130%
Total equity-$249.2M-17.8%
Total assets$293.6M+272%

Cash flow

See full
Operating cash flow-$1.1M-118%
CapEx$33.3K
Free cash flow$920.8K-63.7%

Valuation

See full
Market cap$54.86M+88.7%
Enterprise value$146.86M+120%
P/S1.6×+1.0×

Profitability

See full
Gross margin59.7%-12.3pp
Operating margin-1,034.4%-1,313pp
Net margin-1,162.4%-1,359pp
FCF margin12.2%

Returns & leverage

See full
Return on equity170.9%
Debt / equity0.3×
Current ratio0.1×0.0×

Where this comes from

Reported directly by Scilex Holding Company in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.

The official record: Scilex Holding Company’s 10-Q, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scilex Holding Company's derivative liability, noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scilex Holding Company's derivative liability, noncurrent?
Scilex Holding Company (SCLX) reported derivative liability, noncurrent of $25.54M in Q1 2026.
How has Scilex Holding Company's derivative liability, noncurrent changed year-over-year?
Scilex Holding Company's derivative liability, noncurrent increased by 223.5% year-over-year, from $7.89M to $25.54M.
What is the long-term trend for Scilex Holding Company's derivative liability, noncurrent?
Over 4 years (2021 to 2025), Scilex Holding Company's derivative liability, noncurrent has grown at a 9.1% compound annual growth rate (CAGR), from $35.7M to $50.6M.